Equity capital markets

Vocodia Holdings Corp Announces Closing of $5.95 Million Initial Public Offering and the First IPO to be Listed on The BZX Exchange of CBOE Global Markets

Retrieved on: 
Tuesday, February 27, 2024
Acquisition, Attention, Prospectus, Cboe Global Markets, Marketing, Common stock, CBOE, Sale, Equity capital markets, Common, Form, Series, Unit, Public, Security (finance)

CHICAGO, Feb. 26, 2024 /PRNewswire/ -- Vocodia Holdings Corp (CBOE: VHAI) ("Vocodia" or the "Company"), an AI software company that builds practical AI functions, today announced the closing of its underwritten initial public offering of 1,400,000 Units (collectively the "Units" or "Unit"), each consisting of one share of common stock of the Company, par value $0.0001 ("Common Stock"), one Series A Warrant to purchase one share of Common Stock exercisable at $5.5250 (the "Series A Warrant"), and one Series B Warrant to purchase one share of Common Stock exercisable at an exercise price of $8.5000 (the "Series B Warrant"), at a public offering price of $4.2500 per Unit (the "Public Offering Price").

Key Points: 
  • On February 26, 2024, the underwriters partially exercised their over-allotment option to purchase an additional 70,118 Series B Warrants for a total consideration of $8,764.75.
  • On February 26, 2024, the Company received gross proceeds from the offering, before underwriting discounts and commissions and estimated offering expenses payable by the Company of $5,558,764.75.
  • The securities described above have been offered by Vocodia pursuant to a registration statement on Form S-1, as amended (File No.
  • 333-269489) that was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on February 14, 2024.

Vocodia Holdings Corp. Announces Pricing of $5.95 Million Initial Public Offering, the Inaugural Initial Public Offering on The BZX Exchange of CBOE Global Markets

Retrieved on: 
Monday, February 26, 2024
Acquisition, The Company, Attention, Ticker, Prospectus, Cboe Global Markets, Marketing, Public, Common stock, Sale, Equity capital markets, Form, Series, Security (finance)

CHICAGO, Feb. 22, 2024 /PRNewswire/ -- Vocodia Holdings Corp. ("Vocodia" or the "Company"), an AI software company that builds practical AI functions, today announced the pricing of its underwritten initial public offering of 1,400,000 Units (collectively the "Units" or "Unit"), each consisting of one share of Common Stock of the Company, par value $0.0001 ("Common Stock"), one Series A Warrant to purchase one share of Common Stock at $4.25 (the "Series A Warrant"), and one Series B Warrant to purchase one share of Common Stock at $8.50 (the "Series B Warrant"), at a price to the public of $4.25 per Unit (the "Public Offering Price").

Key Points: 
  • The gross proceeds from the offering, before underwriting discounts and commissions and estimated offering expenses payable by the Company, are expected to be approximately $5,950,000.
  • In addition, the Company has granted the underwriters a 45-day option to purchase up to 210,000 additional Units at the Public Offering Price, less the underwriting discount.
  • The securities described above are being offered by Vocodia pursuant to a registration statement on Form S-1, as amended (File No.
  • The offering is being made only by means of a prospectus forming a part of the effective registration statement.

Raymond James Welcomes Robert Sutherland as Managing Director, Head of Real Estate to the Equity Capital Markets Team

Retrieved on: 
Wednesday, February 21, 2024
Investment, Investment banking, Mergers and acquisitions, Senior, Real estate, Equity capital markets

TORONTO, Feb. 21, 2024 /CNW/ - Raymond James Ltd., the Canadian arm of North American investment dealer Raymond James Financial, Inc., is pleased to welcome Robert Sutherland as Managing Director, Head of Real Estate to the Equity Capital Markets team.

Key Points: 
  • TORONTO, Feb. 21, 2024 /CNW/ - Raymond James Ltd., the Canadian arm of North American investment dealer Raymond James Financial, Inc., is pleased to welcome Robert Sutherland as Managing Director, Head of Real Estate to the Equity Capital Markets team.
  • Mr. Sutherland will oversee and lead the real estate sector for the firm's Investment Banking team in Canada.
  • "We are thrilled to be welcoming Robert to the team," said Craig McDougall, Senior Managing Director, Head of Investment Banking and Mergers and Acquisitions.
  • Robert Sutherland joins Raymond James as an industry leader with over 25 years of experience in the real estate sector with the last 12 years focused on the capital markets.

GE HealthCare Technologies Inc. Prices Secondary Offering of 13,000,000 Shares

Retrieved on: 
Friday, February 16, 2024
Data Management, Health, Technology, Hospitals, Health Technology, Other Health, Pharmaceutical, Varick Street, Attention, J.P. Morgan & Co., Prospectus, Telephone, BNP PARIBAS, J. P. Morgan, Crédit Agricole, File, 2nd Floor, EDGAR, Sale, Equity capital markets, TEL, Form, Communication, Broadridge Financial Solutions, Morgan Stanley, BofA Securities, GE HealthCare, Evercore, Goldman Sachs, General Electric Company, Offering, HSBC, Security (finance)

GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 13,000,000 shares of its common stock (the “GEHC Shares”) at a public offering price of $82.25 per share ($80.605 per share, net of underwriting discount).

Key Points: 
  • GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 13,000,000 shares of its common stock (the “GEHC Shares”) at a public offering price of $82.25 per share ($80.605 per share, net of underwriting discount).
  • GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below).
  • Prior to the closing of the Offering, General Electric Company (“GE”) is expected to exchange the GEHC Shares for indebtedness of GE held by Morgan Stanley Senior Funding, Inc. and Morgan Stanley Bank, N.A.
  • The selling stockholder in the Offering has granted the underwriters an option to purchase additional shares of GE HealthCare common stock at the public offering price less the underwriting discount for 30 days.

GE HealthCare Technologies Inc. Commences Secondary Offering of 13,000,000 Shares

Retrieved on: 
Thursday, February 15, 2024
General Health, Other Health, Health, Pharmaceutical, Health Technology, Varick Street, Attention, J.P. Morgan & Co., Prospectus, Telephone, J. P. Morgan, File, 2nd Floor, EDGAR, Sale, Equity capital markets, TEL, Form, Communication, Broadridge Financial Solutions, Morgan Stanley, BofA Securities, GE HealthCare, Evercore, Goldman Sachs, General Electric Company, Offering, Security (finance)

Prior to the closing of the Offering, General Electric Company (“GE”) is expected to exchange the GEHC Shares for indebtedness of GE held by Morgan Stanley Senior Funding, Inc. and Morgan Stanley Bank, N.A.

Key Points: 
  • Prior to the closing of the Offering, General Electric Company (“GE”) is expected to exchange the GEHC Shares for indebtedness of GE held by Morgan Stanley Senior Funding, Inc. and Morgan Stanley Bank, N.A.
  • (together, the “MS Lenders”), affiliates of Morgan Stanley & Co. LLC, the selling stockholder in the Offering by designation of the MS Lenders.
  • Following the debt-for-equity exchange, if consummated, Morgan Stanley & Co. LLC, as the selling stockholder in the Offering, intends to sell the GEHC Shares to the underwriters in the Offering.
  • The selling stockholder in the Offering has granted the underwriters an option to purchase additional shares of GE HealthCare common stock at the public offering price less the underwriting discount for 30 days.

D.A. Davidson Expands Diversified Industrials Vertical with Two Senior Hires

Retrieved on: 
Thursday, February 15, 2024
Consulting, Banking, Technology, Manufacturing, Professional Services, Other Technology, Other Manufacturing, Textiles, Engineering, Finance, Chemicals, Plastics, Multimedia, Growth, Automation, Equity capital markets, Partner (business rank), Investment banking, Executive officer, Industrial technology, Bank

Davidson has hired Paul Colone and Chris Donegan to expand its Diversified Industrials group to focus on the Specialty Materials and Industrial Automation sectors.

Key Points: 
  • Davidson has hired Paul Colone and Chris Donegan to expand its Diversified Industrials group to focus on the Specialty Materials and Industrial Automation sectors.
  • (Photo: Business Wire)
    “We are excited to continue our methodical expansion of our Diversified Industrials practice,” said Tim Sznewajs, D.A.
  • Davidson Managing Director and Head of Diversified Industrials, Investment Banking.
  • The group has extensive transaction experience serving middle-market clients worldwide across four industry verticals: consumer, diversified industrials, financial institutions, and technology.

Commerzbank increases net profit for 2023 to €2.2 billion – Strategy is delivering

Retrieved on: 
Thursday, February 15, 2024
Rote, Commerzbank, NPE, German Finance Agency, DACH, Bank, TLA, Growth, ECM, Equity capital markets, Risk, Private, Central bank, MBank, European Central Bank, ODDO BHF, PSBC, RWA, Tax, Policy, Common equity, AT1, Annual, Executive officer, Research, Environment, Partnership, Cryptocurrency

On this basis, we will achieve a further increase in net profit for the current year”, said CEO Manfred Knof.

Key Points: 
  • On this basis, we will achieve a further increase in net profit for the current year”, said CEO Manfred Knof.
  • Net interest income rose by a third to €8.368 billion (2022: €6.459 billion), while net commission income was slightly down at €3.386 billion (2022: €3.519 billion).
  • Net profit also rose accordingly: compared to the previous year, net profit after taxes and minority interests increased by 55% to €2.224 billion (2022: €1.435 billion).
  • Revenues amounted to €1.106 billion (Q3 2023: €1.171 billion); the operating result totalled €508 million (Q3 2023: €644 million).

EQS-News: Commerzbank increases net profit for 2023 to €2.2 billion – Strategy is delivering

Retrieved on: 
Thursday, February 15, 2024
Rote, Commerzbank, NPE, German Finance Agency, DACH, Bank, TLA, Growth, ECM, Equity capital markets, Risk, Private, Central bank, MBank, European Central Bank, ODDO BHF, PSBC, RWA, Tax, Policy, Common equity, AT1, Annual, Executive officer, Research, Environment, Partnership, Cryptocurrency

On this basis, we will achieve a further increase in net profit for the current year”, said CEO Manfred Knof.

Key Points: 
  • On this basis, we will achieve a further increase in net profit for the current year”, said CEO Manfred Knof.
  • Net interest income rose by a third to €8.368 billion (2022: €6.459 billion), while net commission income was slightly down at €3.386 billion (2022: €3.519 billion).
  • Net profit also rose accordingly: compared to the previous year, net profit after taxes and minority interests increased by 55% to €2.224 billion (2022: €1.435 billion).
  • Revenues amounted to €1.106 billion (Q3 2023: €1.171 billion); the operating result totalled €508 million (Q3 2023: €644 million).

Evoke Pharma Announces Closing of $7.5 Million Public Offering

Retrieved on: 
Wednesday, February 14, 2024
Attention, Suite, Telephone, Evoke, Fifth Avenue, Sale, Equity capital markets, Form, Series, Capital Group Companies, Form S-1, Security (finance), Metoclopramide, Prescription

"We are pleased to have closed this offering with these fundamental, healthcare-oriented institutional investors," stated Evoke Pharma Chief Executive Officer Dave Gonyer.

Key Points: 
  • "We are pleased to have closed this offering with these fundamental, healthcare-oriented institutional investors," stated Evoke Pharma Chief Executive Officer Dave Gonyer.
  • If the Series A Warrants are exercised in full, the Company would receive an additional $7.5 million in gross proceeds.
  • If the Series B Warrants are exercised in full, the Company would receive an additional $7.5 million in gross proceeds.
  • Evoke intends to use the net proceeds from the public offering for working capital and general corporate purposes.

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Retrieved on: 
Wednesday, February 14, 2024
Attention, Jefferies Group, Prospectus, Telephone, Cardiovascular disease, RBC Capital Markets, EDGAR, Sale, Equity capital markets, Form, Nicollet Mall, Risk, NAMS, State Street, SVB Securities, Madison Avenue, Patient, Common stock, Vesey Street, Offering

The proceeds to the Company from the Offering, before deducting underwriting discounts and commissions and offering expenses payable by the Company, are expected to be approximately $175.3 million.

Key Points: 
  • The proceeds to the Company from the Offering, before deducting underwriting discounts and commissions and offering expenses payable by the Company, are expected to be approximately $175.3 million.
  • In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,383,750 Ordinary Shares at the public offering price, less underwriting discounts and commissions.
  • The Offering is expected to close on or about February 16, 2024, subject to satisfaction of customary closing conditions.
  • Jefferies, Leerink Partners, Piper Sandler, and RBC Capital Markets are acting as joint book-running managers for the Offering.